
Erasca Faces Securities Lawsuit Over Oncology Candidate ERAS-0015
Investors who suffered losses in Erasca, Inc. stock between January 14, 2025, and April 26, 2026, face an August 10, 2026, deadline to seek lead plaintiff status. Hagens Berman is investigating allegations that the biotech firm misled shareholders regarding the competitive edge and safety of its lead cancer drug.























